Virax Biolabs Group Limited
30 Broadwick Street
London, W1F 8LX
United Kingdom
VIA EDGAR
November 29, 2022
U.S. Securities & Exchange Commission
Office of Life Sciences
Division of Corporation Finance
100 F Street, NE
Attn: Ada D. Sarmento
|
Re: |
Virax Biolabs Group Limited |
|
|
Registration Statement on Form F-1 |
|
|
Filed November 21, 2022 |
|
|
File No. 333-268486 |
Pursuant to Rule 461 under the Securities Act of 1933, as amended, Virax Biolabs Group Limited hereby requests acceleration of effectiveness of the above referenced Registration Statement so that it will become effective at 4:00 p.m., Eastern Time, on December 1, 2022, or as soon as thereafter practicable.
|
Very truly yours, |
|
|
|
/s/ James Foster |
|
James Foster Chief Executive Officer |
|
|
DOCPROPERTY "DocID" \* MERGEFORMAT 23223630.1
240437-10002